385 related articles for article (PubMed ID: 16193304)
21. Dipyridyl thiosemicarbazone chelators with potent and selective antitumor activity form iron complexes with redox activity.
Richardson DR; Sharpe PC; Lovejoy DB; Senaratne D; Kalinowski DS; Islam M; Bernhardt PV
J Med Chem; 2006 Nov; 49(22):6510-21. PubMed ID: 17064069
[TBL] [Abstract][Full Text] [Related]
22. Iron chelators of the pyridoxal isonicotinoyl hydrazone class. Relationship of the lipophilicity of the apochelator to its ability to mobilise iron from reticulocytes in vitro.
Ponka P; Richardson DR; Edward JT; Chubb FL
Can J Physiol Pharmacol; 1994 Jun; 72(6):659-66. PubMed ID: 7954097
[TBL] [Abstract][Full Text] [Related]
23. 2-Acetylpyridine thiosemicarbazones are potent iron chelators and antiproliferative agents: redox activity, iron complexation and characterization of their antitumor activity.
Richardson DR; Kalinowski DS; Richardson V; Sharpe PC; Lovejoy DB; Islam M; Bernhardt PV
J Med Chem; 2009 Mar; 52(5):1459-70. PubMed ID: 19216562
[TBL] [Abstract][Full Text] [Related]
24. PCTH: a novel orally active chelator for the treatment of iron overload disease.
Lovejoy DB; Kalinowski D; Bernhardt PV; Richardson DR
Hemoglobin; 2006; 30(1):93-104. PubMed ID: 16540421
[TBL] [Abstract][Full Text] [Related]
25. PCTH: a novel orally active chelator of the aroylhydrazone class that induces iron excretion from mice.
Wong CS; Kwok JC; Richardson DR
Biochim Biophys Acta; 2004 Dec; 1739(1):70-80. PubMed ID: 15607119
[TBL] [Abstract][Full Text] [Related]
26. Chelator-facilitated removal of iron from transferrin: relevance to combined chelation therapy.
Devanur LD; Evans RW; Evans PJ; Hider RC
Biochem J; 2008 Jan; 409(2):439-47. PubMed ID: 17919118
[TBL] [Abstract][Full Text] [Related]
27. Biliary iron excretion in rats following treatment with analogs of pyridoxal isonicotinoyl hydrazone.
Bláha K; Cikrt M; Nerudová J; Ponka HF
Blood; 1998 Jun; 91(11):4368-72. PubMed ID: 9596686
[TBL] [Abstract][Full Text] [Related]
28. Crystal and molecular structure of 2-hydroxy-1-naphthaldehyde isonicotinoyl hydrazone (NIH) and its iron(III) complex: an iron chelator with anti-tumour activity.
Richardson DR; Bernhardt PV
J Biol Inorg Chem; 1999 Jun; 4(3):266-73. PubMed ID: 10439071
[TBL] [Abstract][Full Text] [Related]
29. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
Becker EM; Lovejoy DB; Greer JM; Watts R; Richardson DR
Br J Pharmacol; 2003 Mar; 138(5):819-30. PubMed ID: 12642383
[TBL] [Abstract][Full Text] [Related]
30. Subcellular distribution of desferrioxamine and hydroxypyridin-4-one chelators in K562 cells affects chelation of intracellular iron pools.
Hoyes KP; Porter JB
Br J Haematol; 1993 Oct; 85(2):393-400. PubMed ID: 8280612
[TBL] [Abstract][Full Text] [Related]
31. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.
Lovejoy DB; Richardson DR
Curr Med Chem; 2003 Jun; 10(12):1035-49. PubMed ID: 12678675
[TBL] [Abstract][Full Text] [Related]
32. Pyridoxal isonicotinoyl hydrazone and its analogs: potential orally effective iron-chelating agents for the treatment of iron overload disease.
Richardson DR; Ponka P
J Lab Clin Med; 1998 Apr; 131(4):306-15. PubMed ID: 9579383
[TBL] [Abstract][Full Text] [Related]
33. Identification and characterization of thiosemicarbazones with antifungal and antitumor effects: cellular iron chelation mediating cytotoxic activity.
Opletalová V; Kalinowski DS; Vejsová M; Kunes J; Pour M; Jampílek J; Buchta V; Richardson DR
Chem Res Toxicol; 2008 Sep; 21(9):1878-89. PubMed ID: 18698850
[TBL] [Abstract][Full Text] [Related]
34. Interactions of the pyridine-2-carboxaldehyde isonicotinoyl hydrazone class of chelators with iron and DNA: implications for toxicity in the treatment of iron overload disease.
Chaston TB; Richardson DR
J Biol Inorg Chem; 2003 Apr; 8(4):427-38. PubMed ID: 12761664
[TBL] [Abstract][Full Text] [Related]
35. Design, synthesis, and characterization of new iron chelators with anti-proliferative activity: structure-activity relationships of novel thiohydrazone analogues.
Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2007 Nov; 50(24):6212-25. PubMed ID: 17963372
[TBL] [Abstract][Full Text] [Related]
36. The desferrithiocin (DFT) class of iron chelators: potential as antineoplastic agents.
Kicic A; Chua AC; Baker E
Anticancer Drug Des; 2001; 16(4-5):195-207. PubMed ID: 12049478
[TBL] [Abstract][Full Text] [Related]
37. Lipophilicity of analogs of pyridoxal isonicotinoyl hydrazone (PIH) determines the efflux of iron complexes and toxicity in K562 cells.
Buss JL; Arduini E; Shephard KC; Ponka P
Biochem Pharmacol; 2003 Feb; 65(3):349-60. PubMed ID: 12527328
[TBL] [Abstract][Full Text] [Related]
38. Iron chelators for the treatment of iron overload disease: relationship between structure, redox activity, and toxicity.
Chaston TB; Richardson DR
Am J Hematol; 2003 Jul; 73(3):200-10. PubMed ID: 12827659
[TBL] [Abstract][Full Text] [Related]
39. Coordination chemistry and biology of chelators for the treatment of iron overload disorders.
Bernhardt PV
Dalton Trans; 2007 Aug; (30):3214-20. PubMed ID: 17893764
[TBL] [Abstract][Full Text] [Related]
40. Design, synthesis, and characterization of novel iron chelators: structure-activity relationships of the 2-benzoylpyridine thiosemicarbazone series and their 3-nitrobenzoyl analogues as potent antitumor agents.
Kalinowski DS; Yu Y; Sharpe PC; Islam M; Liao YT; Lovejoy DB; Kumar N; Bernhardt PV; Richardson DR
J Med Chem; 2007 Jul; 50(15):3716-29. PubMed ID: 17602603
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
